ARCHIVES

Funding Opportunities: Lustgarten Foundation Request For Proposals; RFAs Available; NCI Grant Supplements.

This article is from The Cancer Letter archive.

Vol. 29 No. 25 | June 20, 2003

Download PDF Visit The Full Archive

Related Articles

Cell Therapeutics To Appeal FDA Decision on Pixantrone.

September 17, 2010

NCI Criticized For Delays In Development Of New Drugs

January 24, 1975

Obey Attacks NCI, Eppley, Shubick, Asks for Full Report From GAO

June 10, 1977

NTP Board Okays Three Cooperative Agreement Concepts, Including Corn Oil Carcinogens is Test

October 7, 1983

In Brief: King ACCC President, Fleming President Elect; Wyngaarden Says He Doesn’t Oppose Panel

March 25, 1988

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

December 17, 2013